Research on Effectiveness and Safety of the Treatment, Hyperthermic Intraperitoneal Chemotherapy Combined With Tislelizumab and Targeted Therapy, That is Used for High-risk Hepatocellular Carcinoma After R0 Resection
Clinical trial NCT05546619 · UNKNOWN
Trial details
- NCT number
- NCT05546619
- Sponsor
- Sulai Liu
- Status
- UNKNOWN
- Phase
- Not Applicable
- Study type
- INTERVENTIONAL
- Start date
- 2022-08-01
- Primary completion
- 2025-07-31
- Enrollment
- 30
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.